Documentos relacionados

1. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
2. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.
3. Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
4. A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer.
5. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial.
6. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
7. [Review of High-Risk Factors and Adjuvant Chemotherapy Indication in T4-pStage Ⅱ Colon Cancer].
8. Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
9. Neoadjuvant chemotherapy for advanced colonic cancer: standard of care or is the jury still out?
10. Neoadjuvant chemotherapy for locally advanced colonic cancer is the standard of care.